Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy

Clinical Infectious Diseases

Volumn 52, Issue 12, 2011, Pages 1458-1465

  Kesselring, Anouk ^a   Gras, Luuk ^a   Smit, Colette ^a   Van Twillert, Gitte ^b   Verbon, Annelies ^c   De Wolf, Frank ^a   Reiss, Peter ^a,d   Wit, Ferdinand ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Location Alkmaar   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Center for Poverty Related Communicable Diseases   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; ALCOHOL ABUSE; ARTICLE; CANCER RISK; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NON AIDS DEFINING MALIGNANCY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TREATMENT DURATION; UTERINE CERVIX CANCER; VIREMIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; RISK FACTORS; STATISTICS AS TOPIC; VIRAL LOAD; VIREMIA;

EID: 79958104634     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir207     Document Type: Article

References (41)

1. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432. (Pubitemid 40528605)
2. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994- 98: the EuroSIDA study. Lancet 2000; 356:291-296. (Pubitemid 30459587)
3. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
4. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21:685-692. (Pubitemid 46568625)
5. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48:633-639.
6. Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-1753.
7. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736. (Pubitemid 351717418)
8. Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010; 50:1316-1321.
9. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009; 49:1109-1116.
10. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27:884-890.
11. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4:537-547. (Pubitemid 38351710)
12. De FG, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene 2003; 22:6214-6219. (Pubitemid 37281651)
13. Ferry T, Raffi F, Collin-Filleul F, et al. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr 2009; 51:407-415.
14. Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200:79-87.
15. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD41 count-guided interruption of antiretroviral treatment. N Engl JMed 2006; 355:2283-2296. (Pubitemid 44837777)
16. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957-1963. (Pubitemid 47329772)
17. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-1745. (Pubitemid 32259908)
18. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67. (Pubitemid 47017468)
19. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153.
20. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther 2009; 14:1065-1074.
21. Forslund O, Iftner T, Andersson K, et al. Cutaneous human papillomaviruses found in sun-exposed skin: eta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis 2007; 196:876-883. (Pubitemid 47378937)
22. Clifford GM, Rickenbach M, Polesel J, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22:2135-2141.
23. Wong HL, Breen EC, Pfeiffer RM, et al. Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS 2010; 24:1025-1033.
24. Gras L, Van Sighem A, Smit C, Zaheri S, de Wolf F. Monitoring of human immunodeficiency virus (HIV) infection in the Netherlands. 8 A.D. Jan 1.
25. http://www.cphiv.dk/DAD/About/tabid/106/Default.aspx. Accessed 24 March 2011.
26. http://www.cphiv.dk/Portals/0/files/Cancer%20Version%201.1.pdf. Accessed 24 March 2011.
27. Anderson RE, Warner NL. Ionizing radiation and the immune response. Adv Immunol 1976; 24:215-335.
28. Kavanaugh DY, Carbone DP. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am 1996; 10:927-951. (Pubitemid 26240366)
29. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 2007; 19:446-451. (Pubitemid 47356600)
30. Grulich AE. Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009; 4:183-187.
31. Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971; 7:3-25.
32. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103-110. (Pubitemid 46984625)
33. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17:371-375. (Pubitemid 36230918)
34. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-586. (Pubitemid 40723785)
35. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310. (Pubitemid 29168769)
36. Ling PD, Vilchez RA, Keitel WA, et al. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003; 37:1244-1249. (Pubitemid 37372515)
37. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
38. Egger M. Cause or consequence? Peripheral CD4 cell counts and Hodgkin's disease in patients on cART 2010.
39. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998. (Pubitemid 35363648)
40. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117:1137-1146. (Pubitemid 46718398)
41. Giordano TP, Kramer JR. Does HIV infection independently increase the incidence of lung cancer? Clin Infect Dis 2005; 40:490-491. (Pubitemid 40216523)